Get the skinny on GLP-1 safety

December 8 @ 12:00 pm – 1:00 pm EST

Share:

GLP-1 receptor agonists approved by the Food and Drug Administration for diabetes and weight loss have exploded in popularity, with an estimated 1 in 10 adults using them, according to a recent study in the CDC’s Morbidity and Mortality Weekly Report (MMWR).

While some studies have demonstrated that the medications support a loss of about 15-20% body weight, a number of recent reports have emerged about the drugs’ safety. Recently, the FDA required all manufacturers to update their product labels to include warnings about a possible increased risk of a blinding condition called NAION. Other studies have highlighted side effects including gallstones, menstrual changes and osteoporosis, as well as an increased cardiovascular risk in those who discontinue the medications.

In this webinar, pharmacist Diana Isaacs and epidemiologist Ziyad Al-Aly will address what we know about GLP-1s and emerging safety concerns and what journalists should focus on as we continue to report on this important topic.

December 8 @ 12:00 pm – 1:00 pm EST


Karen Blum
  • Moderator

Karen Blum

AHCJ Health Beat Leader for AI and Patient Safety
Karen Blum is AHCJ’s health beat leader for AI and Patient Safety, guiding coverage at the intersection of emerging technology and patient protection. An independent health and science journalist based in the Baltimore area, she previously covered Health IT for AHCJ. Blum has written for publications such as the Baltimore Sun, Pharmacy Practice News, Clinical Oncology News, Clinical Laboratory News, Cancer Today, CURE, AARP.org, General Surgery News and Infectious Disease Special Edition; has covered numerous medical conferences for trade magazines and news services; and has written many profiles and articles on medical and science research as well as trends in health care and health IT. She has been a contest judge for AHCJ’s Awards for Excellence in Health Care Journalism. Blum also is a member of the American Society of Journalists and Authors (ASJA) and chairs its Virtual Education Committee.


Ziyad Al-Aly, M.D.

Director, Clinical Epidemiology Center
Chief, Research and Development Service
VA St. Louis Health Care System

Ziyad Al-Aly, M.D., is a physician-scientist. He is director of the Clinical Epidemiology Center and chief of the Research and Development Service at the VA St. Louis Health Care System and senior clinical epidemiologist at Washington University in St. Louis. His research uses large-scale health data to examine effectiveness and risks of widely used medicines such as GLP-1 drugs, the health effects of environmental exposures, and the long-term effects of infections. He is a TIME100 Health honoree and a Clarivate Highly Cited Researcher.


Diana Isaacs, PharmD

Endocrine Clinical Pharmacy Specialist
Cleveland Clinic Endocrinology & Metabolism Institute

Diana Isaacs, PharmD, is an endocrinology clinical pharmacy specialist. She serves as the co-director of endocrine disorders in pregnancy and the director of education and training in diabetes technology at the Cleveland Clinic Endocrinology and Metabolism Institute. She is also an associate professor in pharmacy practice at Northeast Ohio Medical University College of Pharmacy. She co-hosts the podcast, “Diabetes Dialogue: Technology, Therapeutics and Real-World Perspectives.” She advocates for access and choice in the latest technologies and therapies for people with obesity and diabetes. She was the 2020 ADCES Diabetes Care and Education Specialist of the Year and the 2026 recipient of the ADA Outstanding Educator in Diabetes.

Details